Wells Fargo & Company Corvus Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.76 - $2.41 $8 - $12	5 Added 1.92%	265 $0
Q4 2023 Feb 09, 2024	BUY	$1.08 - $1.92 $14 - $24	13 Added 5.26%	260 $0
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.97 $1 - $2	-1 Reduced 0.4%	247 $0
Q2 2023 Aug 15, 2023	BUY	$1.0 - $3.86 $10 - $38	10 Added 4.2%	248 $0
Q1 2023 May 12, 2023	BUY	$0.65 - $0.92 $1 - $2	3 Added 1.28%	238 $0
Q4 2022 Feb 13, 2023	BUY	$0.74 - $1.04 $4 - $6	6 Added 2.62%	235 $0
Q3 2022 Nov 14, 2022	BUY	$0.71 - $1.17 $7 - $12	11 Added 5.05%	229 $0
Q2 2022 Aug 12, 2022	BUY	$0.87 - $2.03 $189 - $442	218 New	218 $0
Q4 2021 Feb 14, 2022	SELL	$2.34 - $5.31 $425 - $966	-182 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.89 - $8.53 $32 - $145	17 Added 10.3%	182 $1,000
Q2 2021 Aug 16, 2021	BUY	$2.46 - $3.14 $2 - $3	1 Added 0.61%	165 $0
Q1 2021 May 13, 2021	BUY	$2.86 - $4.77 $171 - $286	60 Added 57.69%	164 $1,000
Q4 2020 Feb 09, 2021	BUY	$3.56 - $4.86 $21 - $29	6 Added 6.12%	104 $0
Q3 2020 Nov 05, 2020	BUY	$2.6 - $5.37 $49 - $102	19 Added 24.05%	98 $0
Q1 2020 May 14, 2020	BUY	$1.74 - $5.98 $137 - $472	79 New	79 $0

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.